Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites macaubusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from macaubusiness.com Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is.
08.02.2022 - MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that the Phase I clinical study of its investigational .